About Dematin
Dematin (DMTN) is a protein
from Homo sapiens identified by UniProt accession
Q08495, 405 residues long.
MolForge cross-references it against 0 known binders and
173 disease associations.
Target properties
| Protein name | Dematin |
|---|
| UniProt accession | Q08495 |
|---|
| Gene | DMTN |
|---|
| Organism | Homo sapiens |
|---|
| Length | 405 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (173)
Diseases linked to this target (Open Targets).
- serum gamma-glutamyl transferase measurement · score 0.35
- serum alanine aminotransferase measurement · score 0.33
- low density lipoprotein cholesterol measurement · score 0.29
- apolipoprotein B measurement · score 0.27
- sex hormone-binding globulin measurement · score 0.23
- serum albumin measurement · score 0.21
- calcium measurement · score 0.18
- total cholesterol measurement · score 0.18
- cortical surface area measurement · score 0.14
- Blackfan-Diamond anemia · score 0.09
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q08495-F1 | alphafold | PREDICTED | 63.40 | — |
Amino-acid sequence (405 residues)
MERLQKQPLT SPGSVSPSRD SSVPGSPSSI VAKMDNQVLG YKDLAAIPKD KAILDIERPD LMIYEPHFTY SLLEHVELPR SRERSLSPKS TSPPPSPEVW ADSRSPGIIS QASAPRTTGT PRTSLPHFHH PETSRPDSNI YKKPPIYKQR ESVGGSPQTK HLIEDLIIES SKFPAAQPPD PNQPAKIETD YWPCPPSLAV VETEWRKRKA SRRGAEEEEE EEDDDSGEEM KALRERQREE LSKVTSNLGK MILKEEMEKS LPIRRKTRSL PDRTPFHTSL HQGTSKSSSL PAYGRTTLSR LQSTEFSPSG SETGSPGLQN GEGQRGRMDR GNSLPCVLEQ KIYPYEMLVV TNKGRTKLPP GVDRMRLERH LSAEDFSRVF AMSPEEFGKL ALWKRNELKK KASLF
Explore Dematin with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets